![]() | Jean EndicottDepartment of Psychiatry, Columbia University, New York, NY, USA | Biometrics Research Unit, New York State Psychiatric Institute, 10032 New York, United States of America | ... |
KOL Resume for Jean Endicott
Year | |
---|---|
2019 | Department of Psychiatry, Columbia University, New York, NY, USA |
2018 | Biometrics Research Unit, New York State Psychiatric Institute, 10032 New York, United States of America |
2017 | Department of Psychiatry Columbia University College of Physicians and Surgeons New York NY, USA |
2015 | SPINELLI, ENDICOTT, and GOETZ: Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute. |
2014 | Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY |
2013 | Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York. |
2012 | Department of Psychiatry, Columbia University, New York, NY New York City |
2011 | *Research Methods, Ontario Cancer Biomarker Network, Toronto, Ontario, Canada; †Department of Psychiatry and Department of Neurology, University of Maryland, School of Medicine, Baltimore, MD USA; ‡Translational Medicine, CHDI Foundation, Inc., Princeton NJ; §Research Psychiatrist; ¶University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; #Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; **CHDI Foundation, Inc.; ††Departments of Neurology and Psychiatry, Beth Israel Medical Center, New York, NY; ‡‡Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario Canada; §§School of Psychology and Clinical Language Sciences, University of Reading, U.K.; ##Department of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, IA, USA; ***Department of Psychology & Neuroscience, Baylor University, Waco, TX; †††CNS Drug Development consultant; ‡‡‡Department of Psychology, University of Notre Dame, Notre Dame, Indiana, USA and §§§Department of Psychology, Northern Illinois Unversity, DeKalb IL USA |
2010 | Department of Psychiatry, Weill Cornell Medical College (Dr Leon and Mr Li) and New York State Psychiatric Institute (Dr Endicott), New York |
2009 | Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA New York State Psychiatric Institute, New York |
2008 | New York State Psychiatric Institute/College of Physicians and Surgeons, Columbia University, New York, NY, United States |
2007 | New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY, USA |
2006 | Drs. Endicott and Nee are with the New York State Psychiatric Institute and the Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York; and Drs. Yang and Wohlberg are with Pfizer, New York, NY. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression, Clinical Studies, USA Department of Psychiatry, College of Physicians & Surgeons, Columbia University, and Department of Research Assessment & Training, New York State Psychiatric Institute, New York, New York. New York State Psychiatric Institute, Unit 123, 1051 Riverside Drive, New York, NY 10032, United States |
2005 | Department of Research Assessment and Training, New York State Psychiatric Institute, New York, U.S.A. Columbia University, New York, NY, United States |
2004 | College of Physicians and Surgeons, Columbia University, New York, NY |
2003 | New York State Psychiatric Institute, New York, NY, USA. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression – Clinical Studies |
2002 | From the Department of Psychiatry, Neurobiology, Pharmacology, Biotechnology, University of Pisa, Pisa, Italy; Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA; University of California, San Diego, CA; Columbia University, New York, NY; and the New York State Psychiatric Institute, New York, NY. Columbia University, New York U.S.A., US New York State Psychiatric Institute; and |
2001 | Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, New York University of Iowa College of Medicine, Psychiatry Research, 2-205 MEB, Iowa City, IA 52242-1000, USA |
2000 | New York State Psychiatric Institute, New York 10032, USA. |
1999 | NYS Psychiatric Institute, New York, USA New York State Psychiatric lnstitute, New York City, NY |
1998 | National Institute of Mental Health Collaborative Program on the Psychobiology of Depression, Clinical Studies, San Diego, USA Received December 16, 1997; revised February 7, 1997; accepted February 10, 1997. From the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York, New York. Address correspondence to Dr. Sobin, Rockefeller University, 1230 York Avenue, Box 313, New York, NY 10021-6399. Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute, New York |
1997 | Department of Medical Genetics, New York State Psychiatric Institute, Columbia University, New York, New York Columbia University/NYS Psychiatric Institute, USA |
1996 | Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute New York, NY, USA From the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression–Clinical Studies. New York State Psychiatric Institute, New York, New York |
1995 | National Institute of Mental Health Collaborative Program, Psychobiology of Depression — Clinical Studies, Department of Psychiatry, 2887 JPP, 200 Hawkins Drive, Iowa City, IA 52242, USA Department of Psychiatry , College of Physicians & Surgeons, Columbia University , |
1994 | Department of Psychiatry, Columbia University College of Physicians and Surgeons, 10032, New York, New York, USA New York, N.Y. |
Jean Endicott: Influence Statistics
Concept | World rank |
---|---|
future depressive disorder | #1 |
weeks multivariable analysis | #1 |
enjoyment satisfaction | #1 |
paf scores | #1 |
internal consistency qlesq | #1 |
rater assessment raters | #1 |
groups affective patients | #1 |
capacita quality life | #1 |
improvement psychosocial functioning | #1 |
sisters premenstrual | #1 |
risk rating bipolarity | #1 |
biologic subgroups | #1 |
pathophysiology pmc | #1 |
weeks bivariate analysis | #1 |
affectively probands | #1 |
definizione qualita vita | #1 |
nonaffective syndromes | #1 |
sleep elderly patients | #1 |
nonbipolar patients | #1 |
premenstrual problems criteria | #1 |
spectrum substance abuse | #1 |
ispmd | #1 |
fourth consensus ispmd | #1 |
bipolar sample | #1 |
questions acquaintance | #1 |
d21s1260 locus | #1 |
psychosis phenotypic subtypes | #1 |
male probands alcoholism | #1 |
difference unipolar depression | #1 |
intake diagnoses | #1 |
penetrance correction | #1 |
direction affective switches | #1 |
suicidal behavior psychosis | #1 |
premenstrual syndromes prevalence | #1 |
plhetlod | #1 |
life schizophrenia statistics | #1 |
nonaffective psychopathology | #1 |
pedigrees paternal transmission | #1 |
primary depressive disorder | #1 |
loss spectrum scitals | #1 |
auditable standards diagnosis | #1 |
crosssectional psychopathology | #1 |
biphasic episodes | #1 |
day prhd | #1 |
cycles daily ratings | #1 |
diversity premenstrual | #1 |
assessment premenstrual depression | #1 |
premenstrual complaints order | #1 |
depressionclinical studies | #1 |
compromissione | #1 |
Open the FULL List in Excel | |
Prominent publications by Jean Endicott
The spectrum of substance abuse in bipolar disorder: reasons for use, sensation seeking and substance sensitivity
[ PUBLICATION ]
OBJECTIVES: To examine the spectrum of alcohol and substance abuse, including reasons for use, in patients with bipolar I disorder, compared with patients with substance use disorder and healthy controls, with a specific focus on the relationship between substance use, substance sensitivity, other comorbid psychiatric symptoms and traits related to sensation seeking.
METHODS: This study included 104 patients with bipolar I disorder (BPD I), of whom 57 (54.8%) met DSM-IV criteria for ...
Known for Bipolar Disorder | Sud Patients | Sensation Seeking | Substance Abuse | Exploratory Behavior |
Alcoholism and drug abuse in three groups — bipolar I, unipolars and their acquaintances
[ PUBLICATION ]
OBJECTIVE: Previous work has shown that manic-depressive illness and alcohol abuse are linked. This study further explores the relationship of alcohol and drug abuse in bipolar I patients and unipolar depressives and a comparison group obtained through the acquaintance method.
METHOD: Diagnosis was accomplished according to Research Diagnostic Criteria (RDC): controls = 469; bipolars = 277; unipolar depressives = 678. Systematic data were gathered using the SADS on lifetime and current ...
Known for Drug Abuse | Bipolar Patients | Dual Psychiatry | Younger Age Onset | Depressive Disorder |
INTRODUCTION: The depressive symptoms of bipolar disorder impact health-related quality of life, quality of sleep and functioning. The BOLDER I and II trials demonstrated that quetiapine significantly improves depressive symptoms in patients with acute bipolar depression. Post-hoc analysis of the BOLDER I and II data permits a detailed investigation of the effects of quetiapine on these other measures in this patient population.
METHODS: Secondary analysis was performed on data from ...
Known for Quetiapine Monotherapy | Quality Life | Depressive Symptoms | Acute Bipolar Depression | Bipolar Disorder |
The National Depressive and Manic-Depressive Association Consensus Statement on the Undertreatment of Depression
[ PUBLICATION ]
OBJECTIVE: A consensus conference on the reasons for the undertreatment of depression was organized by the National Depressive and Manic Depressive Association (NDMDA) on January 17-18, 1996. The target audience included health policymakers, clinicians, patients and their families, and the public at large. Six key questions were addressed: (1) Is depression undertreated in the community and in the clinic? (2) What is the economic cost to society of depression? (3) What have been the ...
Known for Treatment Depression | Practice Health | Patients Families | Antidepressive Agents | Drug Utilization |
OBJECTIVE: Previous reports demonstrating quality-of-life impairment in anxiety and affective disorders have relied upon epidemiological samples or relatively small clinical studies. Administration of the same quality-of-life scale, the Quality of Life Enjoyment and Satisfaction Questionnaire, to subjects entering multiple large-scale trials for depression and anxiety disorders allowed us to compare the impact of these disorders on quality of life.
METHOD: Baseline Quality of Life ...
Known for Anxiety Disorders | Life Impairment | Satisfaction Questionnaire | Panic Disorder | Social Phobia |
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder
[ PUBLICATION ]
BACKGROUND: The predictive value of early functional improvement for treatment success at week 8 was assessed in a pooled analysis in patients with major depressive disorder (MDD).
METHODS: Data were pooled from 7 double-blind studies in adult patients with MDD randomly assigned to desvenlafaxine 50 mg/d or placebo. Four levels of treatment success were determined at week 8 for patients with baseline Sheehan Disability Scale (SDS) score > 12 (N = 2156): functional response (SDS ≤12 and ...
Known for Functional Response | Desvenlafaxine 50 | Depressive Disorder | Treatment Success | Week Patients |
Psychosocial Disability in the Course of Bipolar I and II Disorders: A Prospective, Comparative, Longitudinal Study
[ PUBLICATION ]
CONTEXT: Evidence of psychosocial disability in bipolar disorder is based primarily on bipolar I disorder (BP-I) and does not relate disability to affective symptom severity and polarity or to bipolar II disorder (BP-II).
OBJECTIVE: To provide detailed data on psychosocial disability in relation to symptom status during the long-term course of BP-I and BP-II.
DESIGN: A naturalistic study with 20 years of prospective, systematic follow-up.
SETTING: Inpatient and outpatient treatment ...
Known for Psychosocial Disability | Bipolar Disorder Bpii | Longitudinal Studies | Symptom Severity | Manic Hypomanic |
BACKGROUND: The effects of major depressive disorder (MDD) on the course of substance dependence may differ depending on the temporal relationship of depression to dependence. We investigated the effects of MDD on the outcome of substance dependence under 3 circumstances: (1) lifetime onset of MDD prior to lifetime onset of dependence onset, (2) current MDD occurring during a period of abstinence, and (3) current MDD during substance use that exceeded the expected effects of intoxication ...
Known for Substance Dependence | Major Depression | Remission Relapse | Depressive Disorder | Temporal Relationship |
We conducted a 9-cM genome scan in a large bipolar pedigree sample from the National Institute of Mental Health genetics initiative (1060 individuals from 154 multiplex families). We performed parametric and nonparametric analyses using both standard diagnostic models and comorbid conditions thought to identify phenotypic subtypes: psychosis, suicidal behavior, and panic disorder. Our strongest linkage signals (genome-wide significance) were observed on chromosomes 10q25, 10p12, 16q24, ...
Known for Panic Disorder | Suicidal Behavior | Mental Health | Linkage Scan | Phenotypic Subtypes |
Familial Rates of Affective Disorder: A Report From the National Institute of Mental Health Collaborative Study
[ PUBLICATION ]
We examined familial rates of affective disorder and related illness in a cohort of 955 probands studied at five centers in the National Institute of Mental Health Collaborative Study of the Psychobiology of Depression: Boston, Chicago, Iowa City, New York, and St. Louis. Six hundred sixteen of these probands were entered into a family study, and 3423 of their first-degree relatives were evaluated. The probands were divided into five diagnostic groups: schizoaffective-bipolar (n = 37), ...
Known for Affective Disorder | Familial Rates | National Institute | Relatives Probands | Higher Rate |
CONTEXT: The phenomenology of bipolar I disorder affects treatment and prognosis.
OBJECTIVE: To describe the duration of bipolar I mood episodes and factors associated with recovery from these episodes.
DESIGN: Subjects with Research Diagnostic Criteria bipolar I disorder were prospectively followed up for as long as 25 years. The probability of recovery over time from multiple successive mood episodes was examined with survival analytic techniques, including a mixed-effects grouped-time ...
Known for Mood Episodes | Recovery Episode | Bipolar Disorder | Median Duration | Academic Medical Centers |
Key People For Bipolar Disorder
Jean Endicott:Expert Impact
Concepts for whichJean Endicotthas direct influence:Bipolar disorder, Major depression, Major depressive disorder, Depressive disorder, Suicidal behavior, Interpersonal psychotherapy, Psychotic features, Depressive symptoms.
Jean Endicott:KOL impact
Concepts related to the work of other authors for whichfor which Jean Endicott has influence:Bipolar disorder, Major depression, Depressive symptoms, Premenstrual syndrome, Mental health, Quality life, Menstrual cycle.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |